About Akero Therapeutics
Akero Therapeutics is a publicly listed company based in San Francisco (United States) founded in 2017, and was acquired by Novo Nordisk in October 2025. Small molecule therapeutics for metabolic disorders are developed. Akero Therapeutics has raised $135 million across 4 funding rounds from investors including Pfizer, Novo Nordisk and Janus Henderson Investors. The company has 63 employees. Its website akerotx.com draws about 12 thousand monthly visits. Akero Therapeutics offers products and services including Efruxifermin (EFX). Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its legal entity is AKERO THERAPEUTICS, INC. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune; 3 of its 3 listed competitors have raised funding.
Company details
Akero Therapeutics was founded in 2017 and is headquartered in San Francisco, United States. Small molecule therapeutics targeting metabolic disorders, including non-alcoholic steatohepatitis, fibrosis, and liver diseases, are developed by the company. The lead product, Efruxifermin, functions as an agonist of fibroblast growth factor 21. Operations focus on advancing these treatments within the biotechnology sector.
- Headquarters San Francisco, United States
- Employees 63
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phoneβ’β’β’β’ β’β’β’β’
- Website akerotx.com
- Social LinkedIn X
- Acquired by Novo Nordisk (Oct 2025)
- Legal Name Akero Therapeutics, Inc.
- Net Profit-$252.06 M (USD)-66.09as on Dec 31, 2024
- EBITDA-$285.4 M (USD)-65.13as on Dec 31, 2024
- Total Equity Funding$135M (USD)
in 4 rounds
- Latest Funding Round$25M (USD), Post-IPO
Jun 2022
- InvestorsPfizer
& 11 more
- Employee Count63
- Acquired byNovo Nordisk
(Oct 2025)
Products & Services of Akero Therapeutics
Akero Therapeutics offers a comprehensive portfolio of products and services, including Efruxifermin (EFX).
Investigational treatment for metabolic dysfunction-associated steatohepatitis.
Funding Insights of Akero Therapeutics
Akero Therapeutics has successfully raised a total of $135M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $135M
- Total Rounds 4
- Last Round Post-IPO β $25M
- First Round $65M
(Jun 2018)
- Investors Count 11
All 4 funding rounds of Akero Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $25M | Post-IPO | β | β | |
| Jul 2020 | $216.44M | Post-IPO | β | β | β |
| Dec 2018 | $70M | Series B | β | Janus Henderson Investors | |
| Jun 2018 | $65M | Series A | β | Apple Tree Partners, Atlas Venture |
12 investors in total: 12 institutional.
Investors in Akero Therapeutics
Akero Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Novo Nordisk and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare startups are funded by this corporate-backed venture capital entity. | lifesciventure.com | New York, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Apple Tree Partners is engaged in life sciences venture capital. | appletreepartners.com | |||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States |
Investor details for Akero Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Akero Therapeutics
53 people are tracked at Akero Therapeutics (30 in leadership, 7 in board & advisors, 16 in team); the tracked headcount is 63.
| Name | Role | Group |
|---|---|---|
Erik Tillman | Director, Translational Biology & Pharmacology | Leadership |
Catriona Yale | Chief Development Officer | Leadership |
Jonathan Young | COO & Co Founder | Leadership |
William White | CFO & Head of Corporate Development | Leadership |
Tim Rolph | Chief Scientific Officer & Co-Founder | Leadership |
Scott Gangloff | Chief Technical Officer | Leadership |
Reshma Shringarpure | VP, Clinical Research & Medical Affairs | Leadership |
Andrew Cheng | President & CEO | Leadership |
Arin Bose | VP for Drug Substance Process Development | Leadership |
Sean Doyle | Vice President Operations | Leadership |
Lucy N. | Sr Director, Fp&a | Leadership |
John Schembri | VP, Finance & Controller | Leadership |
Brittany de Temple | VP of Development Operations | Leadership |
Libette Luce | VP of Regulatory Affairs | Leadership |
Thomas Quinn | Senior Director, Controller | Leadership |
Lina Patel | Director, Quality Control | Leadership |
Mark Burch | Director Biostatistics | Leadership |
Doreen Chan | Associate Director, Clinical Research | Leadership |
Yasmine Rafidi | Vp, Fp&a | Leadership |
Kimberly Barrett | Director, Clinical Data Management | Leadership |
33 more people are available in the full profile.
Complete people profiles for Akero Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Akero Therapeutics
Akero Therapeutics is a publicly listed company on the NASDAQ with ticker symbol AKRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Jun 2019
- Listed onNASDAQ: AKRO
- Listed entityAkero Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS00973Y1082
- Share price$54.65 (+0.18% on the day) · 2025-12-10
- Market capitalisation$4.50B
- EPS (diluted, trailing year)$-3.75
- Volume (last session)15,312,254
- Analyst consensusNeutral
Financials of Akero Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$252.1M | -$285.4M | |
| 2023 | -$151.8M | -$172.8M | |
| 2022 | -$112.0M | -$114.9M | |
| 2021 | -$100.8M | -$100.6M | |
| 2020 | -$79.2M | -$79.9M |
Detailed financial statements for Akero Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Akero Therapeutics
5 dated milestones of Akero Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Akero Therapeutics is founded.
- Funding First funding round of $65.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $25.0M.
- Exit Acquired by Novo Nordisk.
Competitors of Akero Therapeutics
Akero Therapeutics has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. |
Detailed competitors of Akero Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Akero Therapeutics
The website of Akero Therapeutics (akerotx.com) receives about 12.4K visits a month and ranks #1,579,833 among all websites worldwide, #2,116 in Biotechnology and Pharmaceuticals.
- Monthly visits12.4K
▼ 27.7% vs previous month
- Unique visitors7.4K
per month
- Global rank#1,579,833
among all websites
- Category rank#2,116
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.5
- Average visit12 sec
- DevicesDesktop 24% Β· Mobile 76%
Websites whose visitors overlap most with Akero Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biopharmadive.com | 100% | 680.7K | #208,628 | View details |
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Akero Therapeutics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Akero Therapeutics
Complete news archive for Akero Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Akero Therapeutics
Akero Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Akero Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Akero Therapeutics is a funded company, having raised a total of $135M across 4 funding rounds to date. The company's 1st funding round was a Series A of $65M, raised on Jun 2018.
Akero Therapeutics has 63 employees.
Akero Therapeutics was founded in 2017 and is headquartered in San Francisco, United States. Small molecule therapeutics targeting metabolic disorders, including non-alcoholic steatohepatitis, fibrosis, and liver diseases, are developed by the company. The lead product, Efruxifermin, functions as an agonist of fibroblast growth factor 21. Operations focus on advancing these treatments within the biotechnology sector.
Akero Therapeutics's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Altimmune.
Akero Therapeutics offers Efruxifermin (EFX).
Yes, Akero Therapeutics is publicly traded on NASDAQ under the ticker symbol AKRO.
Akero Therapeutics has 12 investors. Key investors include Pfizer, Novo Nordisk, Janus Henderson Investors, Atlas Venture, and LifeSci Venture Partners.
Akero Therapeutics operates through Akero Therapeutics, Inc..
Yes. Akero Therapeutics was acquired by Novo Nordisk in October 2025.

